Yenidoğanda indirekt hiperbilirubinemi tanı ve tedavisi; derleme

Yıl 2020, , 463 - 475, 14.05.2020

Özmert M.a. Özdemir

https://doi.org/10.31362/patd.663348

Öz

İndirekt hiperbilirubinemiye bağlı yenidoğan sarılığı term ve preterm bebeklerde çok sık görülmektedir. Yenidoğan sarılığı tedavisinde amaç bilirubinin beyne zarar verecek düzeylere çıkmasını önlemek ve yüksek bilirubin düzeylerini hızla düşürmektir. Bu amaçla, yenidoğanlar taburculuk öncesi sarılık açısından değerlendirilmeli, bu bebeklere iyi bir emzirme eğitimi verilmeli ve takip planı yapılmalıdır. Sarılık saptanan bebeklerde serum total bilirubin ve/veya transkutan bilirubin ölçümü ile risk zonu değerlendirilmeli ve Türk Neonatoloji Derneği rehberi eşliğinde postnatal yaş ve risk faktörlerine göre serum total bilirubin düzeyi fototerapi eşik değerine ulaşmış ise fototerapi başlanmalıdır. Serum total bilirubin düzeyi kan değişim sınırına yaklaşık 3 mg/dl yakın veya bilirubin artış hızı saatte 0,5 mg/dl’yi geçiyor ise yoğun fototerapi başlanılması, fototerapi eşik değerinde ise standart fototerapi ile tedavi edilmesi uygundur. Fototerapi etkinliği için 4-6 saat sonra bilirubin düzeyi ölçülmeli, bilirubin değeri fototerapi eşik değerinin yaklaşık 3 mg/dl altına düşmüş ise fototerapi kesilmeli ve 12-24 saat sonra rebound bilirubin düzeyi ölçülmelidir. Yoğun fototerapiye rağmen bilirubin düzeyi artıyor ve postnatal yaş ve risk faktörlerine göre kan değişimi eşik değerine ulaşmışsa ya da akut bilirubin ensefalopati bulguları varsa tecrübeli kişilerce, yoğun bakım şartlarında uygun kan ile acil kan değişimi yapılmalıdır.

Anahtar Kelimeler

Yenidoğan, sarılık, tanı, tedavi

Diagnosis and therapy of neonatal indirect hyper bilirubinemia.

Öz

Abstract

Neonatal jaundice due to unconjugated
hyperbilirubinemia is very common in term and preterm infants. The aim of the
therapy of neonatal jaundice is to prevent the elevation of bilirubin levels
that will be harmful to the brain and to rapidly decrease increased bilirubin
levels. For this purpose, newborns should be evaluated for jaundice before
discharge, a good breastfeeding education should be given to these babies and a
follow-up plan should be made. Infants with jaundice should be evaluated by
serum total bilirubin and/or transcutaneous bilirubinometry measurement and if bilirubin
level reaches the phototherapy (PT) threshold according to postnatal age and
risk factors accompanied by Turkish Neonatal Society guideline, PT should be
started. If bilirubin level is close to the exchange transfusion (ET) limit of
approximately 3 mg/dl or if bilirubin increase rate exceeds 0.5 mg/dl per hour,
it is appropriate to start intensive PT. If bilirubin reaches the threshold of
PT, treatment with standard PT is appropriate. The bilirubin level should be
measured after 4 to 6 hours for PT activity, if bilirubin value has dropped to
approximately 3 mg/dl below the PT threshold, PT should be discontinued and rebound
bilirubin level should be measured after 12-24 hours. In spite of intensive PT,
if bilirubin level increases and reaches the ET threshold according to
postnatal age and risk factors, or if there are signs of acute bilirubin
encephalopathy, emergency ET should be performed by individuals experienced in
this field with appropriate blood in the intensive care conditions. 

Anahtar Kelimeler

Newborn, jaundice, diagnosis, treatment

Kaynakça

• 1. Kaplan M, Wong RJ, Sıbley E, Stevenson DK. Neonatal jaundice and liver diseases. In: Martin RJ, Fanaroff AA, Walsh MC, eds. Fanaroff & Martin’s neonatal-perinatal medicine: diseases of the fetus and infant. 10th ed. Philadelphia: Elsevier Saunders, 2015;1618-1673. 2. Çoban A, Kaynak Türkmen M, Gürsoy T. Türk Neonatoloji Derneği Yenidoğan Sarılıklarında Yaklaşım, İzlem ve Tedavi Rehberi 2014. 3. Cayabyab R, Ramanathan R. High unbaund bilirubin fora ge: a neurotoxin with majör effects on the developing brain. Pediatr Res 2019;85:183-190. DOI: 10.1038/s41390-018-0224-4 4. Johnson L, Bhutoni VK. The clinical syndrome of bilirubin-induced neurologic dysfuntion. Semin Perinatol 2011;35:101-113. DOI: 10.1053/j.semperi.2011.02.003 5. American Academy of Pediatrics, Clinical Practice Guideline, Subcommittee on Hyperbiliribunemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114:297-316. https://doi.org/10.1542/peds.114.1.297 6. Maisels MJ, Watchko JF. Neonatal hyperbilirubinemia. In: Fanaroff AA, Fanaroff JM, eds. Klaus & Fanaroff’s care of the high-risk Neonate. 6th ed. Philadelphia: Elsevier Saunders, 2013;310-346. 7. Maisels MJ, Watchko JF. Jaundice. In: MacDonald MG, Seshia MMK, eds. Avery’s neonatology. Pathophysiology and management of the newborn. 7th ed. Philadelphia: Wolters Kluwer, 2016;587-645. 8. Neonatal-Jaundice identification and management in neonates ≥ 32 weeks gestation. NSW Goverment Guideline, GL_2016-027, http://www.health.nsw.gov.au/policies/ 9. National Collaborating Centre for Women’s and Children’s Health. Neonatal jauindice. Londan: RCOG Press, 2010 May. 10. Türk Neonatoloji Derneği tanı ve tedavi protokolleri No 2. Türk Neonatoloji Derneği Bülteni. Sayı 6-Güz 2002;12-18. 11. Rennie JM, Sehgal A, De A, Kendall GS, Cole TJ. Range of UK practice regarding thresholds for phototherapy and exchange transfusion in neonatal hyperbilirubinaemia. Arch Dis Child Fetal Neonatal Ed 2009;94:F323–F327. http://dx.doi.org/10.1136/adc.2008.147686 12. Kaplan M, Merlob P, Regev R. Israel guidelines for the management of neonatal hyperbilirubinemia and prevention of kernicterus. J Perinatol 2008;28:389-397. DOI: 10.1038/jp.2008.20 13. Treatment of uncojugated hyperbilirubinemia in term and late preterm infants - UpToDate. www.uptodate.com ©2019 UpToDate. 14. Bratlid D, Nakstad B, Hansen TWR. National guidelines for the treatment of jaundice in the newborn. Acta Paediatr 2011;100:499-505. https://doi.org/10.1111/j.1651-2227.2010.02104.x 15. van Imhoff DE, Dijk PH, Hulzebos CV, BARTial study group of the Netherlands Neonatal Research network. Uniform treatment thresholds for hyperbilirubinemia in preterm infants: background and synopsis of a national guideline. Early Hum Dev 2011;87(8):521-525. DOI: 10.1016/j.earlhumdev.2011.04.004 16. Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. An approach to the management of hyperbilirubinemia in the preterm infants less than 35 weeks of gestation. J Perinatol 2012;32:660-664. DOI: 10.1038/jp.2012.71 17. Güzoğlu N, Tandırcıoğlu ÜA, Aliefendioğlu D. Management of hyperbilirubinemia in preterm infants in Turkey. Turk J Med Sci 2016;46:401-403. DOI: 10.3906/sag-1411-147 18. Morioka I. Hyperbilirubinemia in preterm infants in Japan: new treatment criteria. Pediatr Int 2018;60:684-690. https://doi.org/10.1111/ped.13635 19. Morioka I, Nakamura H, Iwatani S, Wong RJ, Lijima K. International perspectives: Clinical kernicterus in preterm infants in Japan. NeoReviews 2016;17:e124–30. 20. Lamola AA. A pharmacologic view of phototherapy. Clin Perinatol 2016;43:259-276. https://doi.org/10.1016/j.clp.2016.01.004 21. Morris BH, Tyson JE, Stevenson DK, et al. Efficacy of phototherapy devices and outcomes among extremely low birth weight infants: multı-center observational study. J Perinatol 2013;33(2):126-133. DOI: 10.1038/jp.2012.39 22. Okwundu CI, Okoromah CAN, Shah PS. Prophylactic phototherapy for preventing jaundice in preterm or low birth weight infants. Cochrane Database of Systematic Reviews 2012, CD007966. DOI: 10.1002/14651858.CD007966.pub2 23. Morris BH, Oh W, Tyson JE, et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. N Engl J Med 2008;359:1885-1896. DOI: 10.1056/NEJMoa0803024 24. Hyperbilirubinemia in the preterm infant (less than 35 weeks gestation) – UpToDate. www.uptodate.com ©2019 UpToDate. 25. Woodgate P, Jardine LA. Neonatal jaundice: phototherapy. BMJ Clin Evid. 2015; May 22, pii: 0319. 26. Lee Wan Fei S, Abdullah KL. Effect of turning vs. supine position under phototherapy on neonates with hyperbilirubinemia: a systematic review. J Clin Nurs. 2015;24:672-682. https://doi.org/10.1111/jocn.12712 27. Olusanya BO, Imam ZO, Emokpaeb AA, Iskender IF. Revisiting the criteria for exchange transfusion for severe neonatal hyperbilirubinemia in resource-limited settings. Neonatology 2016;109:97-104. https://doi.org/10.1159/000441324 28. Çoban A, Kaynak Türkmen M, Gürsoy T. Türk Neonatoloji Derneği yenidoğan sarılıklarında yaklaşım, izlem ve tedavi rehberi. Turk Pediatri Ars 2018;53(Suppl 1):S172-S179. DOI: 10.5152/TurkPediatriArs.2018.01816 29. Perlman JM, Volpe JJ. Bilirubin. In: Volpe JJ, ed. Volpe’s neurology of the newborn. 6th ed. Philadelphia: Elsevier, 2018;730-762. 30. Girelli G, Antoncecchi S, Casadei AM, et al. Recommendations for transfusion therapy in neonatology. Blood Transfus 2015;13:484-497. DOI: 10.2450/2015.0113-15 31. Perk Y, Atasay B, Çetinkaya M. Türk Neonatoloji Derneği kan ürünleri transfüzyon rehberi önerisi 2016. 32. Kapoor D, Singh P, Seth A. Current perspective of Exchange transfusion. Indian Pediatr 2017;54:961-962. DOI: 10.1007/s13312-017-1191-2 33. Fasano RM, Luban NLC. Transfusion practices. In: De Alarcon PA, Werner EJ, Christensen RD, eds. Neonatal hematology, pathogenesis, diagnosis and management of hematologic problems. 2nd ed. Cambridge University Press: 2013;303-327. 34. Yu C, Li H, Zhang O, He H, Chen X, Hua Z. Report about term infants with severe hyperbilirubinemia undergoing Exchange transfusion in Southwestern China during an 11-year period, from 2001 to 2011. PLos One 2017;12(6):e0179550. https://doi.org/10.1371/journal.pone.0179550 35. Ogunlesi TA, Lesi FEA, Oduwole O. Prophylactic intravenous calcium therapy for exchange blood transfusion in the newborn (Review). Cochrane Database of Systematic Reviews 2017, Issue 10. Art. No.: CD011048. DOI: 10.1002/14651858.CD011048.pub2 36. Canadian Paediatric Society. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks' gestation) - Summary. Paediatr Child Health. 2007;12(5):401-18. DOI: 10.1093/pch/12.5.401 37. Buhatani VK, Wong RJ, Stevenson DK. Hyperbilirubinemia in preterm neonates. Clin Perinatol 2016;43:215-232. https://doi.org/10.1016/j.clp.2016.01.001 38. Zwiers C, Scheffer-Rath MEA, Lopriore E, de Haas M, Liley HG. Immunoglobulin for alloimmune hemolytic disease in neonates (Review). Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No.: CD003313. DOI: 10.1002/14651858.CD003313.pub2 39. Olusanya BO, Ogunlesi TA, Kumar P, et al. Management of late-preterm and term infants with hyperbilirubinaemia in resource-constrained settings. BMC Pediatrics 2015;15:39. DOI: 10.1186/s12887-015-0358-z 40. Ree IMC, Smits-Wintjens VEHJ, van der Bom JG, van Klink JMM, Oepkes D, Lopriore E. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017;10(7):607-616. https://doi.org/10.1080/17474086.2017.1331124 41. Gu J, Zhu Y, Zhao J. The efficacy of intravenous fluid supplementation for neonatal hyperbilirubinemia: a meta-analysis of randomized controlled studies. J Matern Fetal Neonatal Med. 2019;17:1-6. https://doi.org/10.1080/14767058.2019.1688295 42. Lai NM, Ahmad Kamar A, Choo YM, Kong JY, Ngim CF. Fluid supplementation for neonatal unconjugated hyperbilirubinaemia (Review). Cochrane Database of Systematic Reviews 2017, Issue 8. Art. No.: CD011891. DOI: 10.1002/14651858.CD011891.pub2 43. Deshmukh J, Deshmukh M, Patole S. Probiotics for the management of neonatal hyperbilirubinemia: a systematic review of randomized controlled trials. J Matern Fetal Neonatal Med. 2019;32(1):154-163. https://doi.org/10.1080/14767058.2017.1369520